Clinical trials: Concentration
Infertility, Female, Infertility, Male
Effects of Antioxidant Supplementation of Culture Media on IVF Embryos
The goal of this clinical trial is to investigate the impact of repeated antioxidant supplementation on blastocyst utilization and expansion rates in embryos under different oxygen concentrations.
- Trial name
- NCT05919186
- Testing
- EmbryORP®, O2 tension 20%, O2 tension 5%
- Where
- Mexico
- Volunteers
- 293 people
- Sponsor
- Liliana Berenice Ramírez Domínguez
Dry Eye Disease
BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial
Trial RX01-BL1107-1202 is designed to identify the lowest effective concentration of BL1107 required for complete resolution of conjunctival hyperemia in participants with DED.
- Trial name
- BRIGHT (NCT07778888)
- Testing
- BL1107
- Volunteers
- 20 people
- Sponsor
- Bausch & Lomb Incorporated
Blood Pressure, HDL Low
Effects of a 10 Component Dietary Supplement on Health and the Quality of Life
This open-label field trial evaluates the effects of treatment with a multi-pathway dietary supplement (Stem Cell 100+) that has been commercially available for several years.
- Conditions
- Blood Pressure, HDL Low, Stress, Lung Function Decreased
- Trial name
- NCT03052491
- Testing
- Stem Cell 100+
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Centagen, Inc.
Sweat Rate
Normative Data for Sweating Rate, Sweat Sodium Concentration and Sweat Sodium Loss in Female Athlete
The main objectives are to determine sweat sodium concentration [Na+], whole body sweat rate (WBSR) and rate of sweat sodium loss (RSSL) in female athletes aged 13 and above during their normal planned training session across…
- Trial name
- NCT06995768
- Testing
- Sweat patch
- Where
- United States
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Healthy
Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation
The purpose of this study is to assess the concentration of besifloxacin compared to gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the drug instilled topically into the study eye.
- Trial name
- NCT00905762
- Testing
- Gatifloxacin, Moxifloxacin, Besifloxacin
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Infertility
Diafert® for Embryo Selection and Fertility Improvement
Prospective, single-center, single-blind, randomized, controlled, two-arm, interventional study.
- Trial name
- DESTINy (NCT02593461)
- Testing
- Daifert, Control Group
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Forest Laboratories
Discogenic Pain
Study Investigating STA363 Compared to Placebo in Patients With Chronic Discogenic Low Back Pain
This is a phase IIb, prospective, multi-country, multicenter, randomized, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and transformation of NP following single intradiscal injection…
- Trial name
- STA-02 (NCT04673461)
- Testing
- STA363 containing 90 mg (60 mg/mL) lactic acid, STA363 containing 180 mg (120 mg/mL) lactic acid
- Where
- 17 sites in Netherlands, Russia and 1 more
- Volunteers
- 110 people
- Sponsor
- Stayble Therapeutics
Attention Deficit Hyperactivity Disorder
Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
The purpose of this study is to evaluate the long-term safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.
- Trial name
- NCT02704390
- Testing
- ORADUR®-Methylphenidate
- Where
- 3 sites in Taiwan
- Volunteers
- 64 people
- Sponsor
- Orient Pharma Co., Ltd.
Kidney Transplantation, Transplantation
Pre-transplant Assessment of Tacrolimus Blood Level Concentration, as a Predictor of Tacrolimus Dose Requirements After Kidney Transplantation
The purpose of this study is to evaluate two groups of kidney transplant recipients, to determine the proportion of patients that achieve therapeutic blood concentrations of tacrolimus by Day 3 after transplantation.
- Trial name
- NCT00297310
- Testing
- tacrolimus
- Volunteers
- 89 people
- Sponsor
- Janssen-Cilag Pty Ltd
Mild Cognitive Impairment, Alzheimer's Disease
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease
This study is being conducted to determine the safety, tolerability, pharmacokinetics, and effects of EVP-0962 on cerebral spinal fluid Amyloid concentrations in healthy subjects and in subjects with mild cognitive impairment or…
- Trial name
- NCT01661673
- Testing
- EVP-0962
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- FORUM Pharmaceuticals Inc
Attention Deficit Hyperactivity Disorder
Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD)
Children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) who are not tolerating or not responding well to stimulant therapy will be included in this study.
- Trial name
- ADHD SWITCH (NCT00760747)
- Testing
- Atomoxetine
- Where
- 6 sites in Australia, Mexico and 1 more
- Volunteers
- 112 people
- Sponsor
- Eli Lilly and Company
Septic Shock
Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
This is a double-blind, placebo-controlled, randomized, multicenter proof of concept and dose-finding phase II study using two doses of ADRECIZUMAB in patients with early septic shock and a bio-ADM plasma concentration at…
- Trial name
- AdrenOSS-2 (NCT03085758)
- Testing
- Adrecizumab
- Where
- 30 sites in Belgium, France and 2 more
- Volunteers
- 301 people
- Sponsor
- Adrenomed AG
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT02466386
- Testing
- SPD489
- Where
- 50 sites in United States
- Volunteers
- 113 people
- Sponsor
- Shire
ADHD
A Comparative Study to Evaluate a Novel Algorithm As a Diagnostic Aid for ADHD in Youth Ages 6-17.
This study aims to demonstrate the accuracy of the MT1 algorithm using the MindTension biometric sensor device as a diagnostic aid for healthcare providers in diagnosing ADHD in youth ages ≥ 6 to ≤17 years.
- Trial name
- NCT06728969
- Testing
- MT1 Auditory startle response patterns analysis algorithm, T.O.V.A. Continuous Performance Test
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MindTension
ADHD
PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in pediatric subjects between 6 to 12 years of age.
- Trial name
- NCT03172481
- Testing
- PRC-063 oral capsules
- Where
- 6 sites in United States
- Volunteers
- 156 people
- Sponsor
- Purdue Pharma, Canada
Attention-Deficit/Hyperactivity Disorder
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients
- Trial name
- NCT02736656
- Testing
- SPN-812
- Where
- 16 sites in United States
- Volunteers
- 1,400 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Eye Infections, Bacterial
Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers
To compare the ocular tolerance, safety and ocular pharmacokinetics of 3 concentrations (0.5% - 1.0% - 1.5%) and the vehicle of T1225.
- Trial name
- NCT00357539
- Testing
- Azithromycin (T1225)
- Where
- France
- Volunteers
- healthy volunteers welcome
- Sponsor
- Laboratoires Thea
Dermatitis, Atopic
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
The purpose of this study is to determine the safety and efficacy of AN2728 Topical Ointment, 2% and 0.5%, administered once a day (QD) or twice a day (BID), in the treatment of adolescents with atopic dermatitis (AD)
- Trial name
- NCT01602341
- Testing
- AN2728 Topical Ointment, 2% QD, AN2728 Topical Ointment, 0.5% QD, AN2728 Topical Ointment, 2% BID
- Where
- 17 sites in United States, Australia
- Volunteers
- 86 people
- Sponsor
- Pfizer
Attention-deficit/Hyperactivity Disorder
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
The primary objective of this study is to evaluate the long-term maintenance of efficacy of Extended-Release Guanfacine HCl in children and adolescents (6-17 years) with attention-deficit/hyperactivity disorder (ADHD) who respond…
- Trial name
- NCT01081145
- Testing
- Extended-release Guanfacine Hydrochloride
- Where
- 81 sites in United States, Belgium and 8 more
- Volunteers
- 528 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA).
- Trial name
- NCT03638466
- Testing
- Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.